BioCryst (BCRX) Revenue by Segment

Separates income by business lines—such as product sales, royalties, licensing, and collaboration or milestone payments—to reveal whether BioCryst depends on one commercial product or partner. A diversified segment mix suggests multiple revenue engines and steadier cash flow, whereas reliance on a single segment increases sensitivity to clinical, commercial, or partner-related setbacks.

ORLADEYO is clearly the recurring revenue engine — steady, multi‑year growth with Q2 showing ~10% YoY — while the “Other” line is highly lumpy, driven by one‑time license/divestiture receipts (the recent quarter includes the ~€55.7M upfront). Management raised total revenue guidance largely because of those non‑recurring items but kept ORLADEYO guidance unchanged, signaling durable underlying demand (improving paid rates, early pediatric uptake) even as competition from new injectables and pediatric manufacturing timing remain watchpoints.